Is CLPT or CNMD more profitable?

CONMED has a net margin of 4.12% compared to ClearPoint Neuro's net margin of -81.76%. CONMED's return on equity of 14.31% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets ClearPoint Neuro -81.76% -188.09% -40.88% CONMED 4.12% 14.31% 6.33%

ClearPoint Neuro (CLPT) Competitors

$13.83 +0.09 (+0.66%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.86 +0.03 (+0.18%)

As of 09/18/2026 07:30 PM Eastern

Compare

CLPT vs. OMCL, KMTS, CNMD, DRTS, and AORT

Should you buy ClearPoint Neuro stock or one of its competitors? ClearPoint Neuro's main competitors and comparable companies include Omnicell (OMCL), Kestra Medical Technologies (KMTS), CONMED (CNMD), Alpha Tau Medical (DRTS), and Artivion (AORT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ClearPoint Neuro compare to Omnicell?

Omnicell (NASDAQ:OMCL) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Omnicell has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.24	$2.05M	$0.84	38.37
ClearPoint Neuro	$36.97M	11.41	-$25.54M	-$1.18	N/A

Omnicell has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

97.7% of Omnicell shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Omnicell presently has a consensus price target of $57.86, suggesting a potential upside of 79.51%. ClearPoint Neuro has a consensus price target of $25.67, suggesting a potential upside of 85.59%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Omnicell had 2 more articles in the media than ClearPoint Neuro. MarketBeat recorded 2 mentions for Omnicell and 0 mentions for ClearPoint Neuro. Omnicell's average media sentiment score of 0.83 beat ClearPoint Neuro's score of 0.00 indicating that Omnicell is being referred to more favorably in the media.

Company	Overall Sentiment
Omnicell	Positive
ClearPoint Neuro	Neutral

Omnicell has a net margin of 3.13% compared to ClearPoint Neuro's net margin of -81.76%. Omnicell's return on equity of 5.66% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

Summary

Omnicell beats ClearPoint Neuro on 12 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

ClearPoint Neuro has a net margin of -81.76% compared to Kestra Medical Technologies' net margin of -140.43%. Kestra Medical Technologies' return on equity of -63.83% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

Kestra Medical Technologies presently has a consensus price target of $28.38, indicating a potential upside of 16.15%. ClearPoint Neuro has a consensus price target of $25.67, indicating a potential upside of 85.59%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Kestra Medical Technologies had 19 more articles in the media than ClearPoint Neuro. MarketBeat recorded 19 mentions for Kestra Medical Technologies and 0 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.00 beat Kestra Medical Technologies' score of -0.02 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Kestra Medical Technologies	Neutral
ClearPoint Neuro	Neutral

ClearPoint Neuro has lower revenue, but higher earnings than Kestra Medical Technologies. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$95.13M	15.30	-$131.61M	-$2.67	N/A
ClearPoint Neuro	$36.97M	11.41	-$25.54M	-$1.18	N/A

30.1% of ClearPoint Neuro shares are held by institutional investors. 5.3% of Kestra Medical Technologies shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kestra Medical Technologies has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summary

ClearPoint Neuro beats Kestra Medical Technologies on 9 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to CONMED?

ClearPoint Neuro (NASDAQ:CLPT) and CONMED (NYSE:CNMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 0.3% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ClearPoint Neuro has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, CONMED has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

In the previous week, CONMED had 1 more articles in the media than ClearPoint Neuro. MarketBeat recorded 1 mentions for CONMED and 0 mentions for ClearPoint Neuro. CONMED's average media sentiment score of 0.45 beat ClearPoint Neuro's score of 0.00 indicating that CONMED is being referred to more favorably in the news media.

Company	Overall Sentiment
ClearPoint Neuro	Neutral
CONMED	Neutral

ClearPoint Neuro presently has a consensus price target of $25.67, indicating a potential upside of 85.59%. CONMED has a consensus price target of $41.40, indicating a potential downside of 8.85%. Given ClearPoint Neuro's stronger consensus rating and higher probable upside, research analysts plainly believe ClearPoint Neuro is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CONMED	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

CONMED has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	11.41	-$25.54M	-$1.18	N/A
CONMED	$1.37B	0.99	$47.06M	$1.85	24.55

CONMED has a net margin of 4.12% compared to ClearPoint Neuro's net margin of -81.76%. CONMED's return on equity of 14.31% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
CONMED	4.12%	14.31%	6.33%

Summary

CONMED beats ClearPoint Neuro on 9 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Alpha Tau Medical has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Alpha Tau Medical has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -81.76%. Alpha Tau Medical's return on equity of -138.12% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-138.12%	-81.68%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

ClearPoint Neuro has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A
ClearPoint Neuro	$36.97M	11.41	-$25.54M	-$1.18	N/A

Alpha Tau Medical presently has a consensus target price of $15.40, suggesting a potential upside of 1.05%. ClearPoint Neuro has a consensus target price of $25.67, suggesting a potential upside of 85.59%. Given ClearPoint Neuro's higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alpha Tau Medical had 5 more articles in the media than ClearPoint Neuro. MarketBeat recorded 5 mentions for Alpha Tau Medical and 0 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.00 beat Alpha Tau Medical's score of -0.48 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Tau Medical	Neutral
ClearPoint Neuro	Neutral

Summary

ClearPoint Neuro beats Alpha Tau Medical on 8 of the 15 factors compared between the two stocks.

How does ClearPoint Neuro compare to Artivion?

Artivion (NYSE:AORT) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

86.4% of Artivion shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Artivion has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Artivion has higher revenue and earnings than ClearPoint Neuro. Artivion is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.58	$9.77M	-$0.07	N/A
ClearPoint Neuro	$36.97M	11.41	-$25.54M	-$1.18	N/A

Artivion has a net margin of -0.67% compared to ClearPoint Neuro's net margin of -81.76%. Artivion's return on equity of 6.07% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
ClearPoint Neuro	-81.76%	-188.09%	-40.88%

In the previous week, Artivion had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 4 mentions for Artivion and 0 mentions for ClearPoint Neuro. Artivion's average media sentiment score of 0.77 beat ClearPoint Neuro's score of 0.00 indicating that Artivion is being referred to more favorably in the media.

Company	Overall Sentiment
Artivion	Positive
ClearPoint Neuro	Neutral

Artivion currently has a consensus target price of $44.83, suggesting a potential upside of 91.77%. ClearPoint Neuro has a consensus target price of $25.67, suggesting a potential upside of 85.59%. Given Artivion's stronger consensus rating and higher possible upside, equities analysts clearly believe Artivion is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Artivion beats ClearPoint Neuro on 12 of the 16 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$421.87M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-11.72	25.34	275.49	25.40
Price / Sales	11.41	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	13.97	5.69	10.46	6.33
Net Income	-$25.54M	$151.55M	$3.49B	$358.33M
7 Day Performance	0.80%	0.66%	0.59%	1.12%
1 Month Performance	-8.95%	-3.33%	-1.74%	-2.39%
1 Year Performance	23.48%	6.79%	18.13%	5.35%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	2.0941 of 5 stars	$13.83 +0.7%	$25.67 +85.6%	+23.5%	$421.87M	$36.97M	N/A	172
OMCL Omnicell	4.1975 of 5 stars	$32.77 -2.2%	$57.86 +76.5%	+2.8%	$1.48B	$1.25B	38.82	3,580	Positive News
KMTS Kestra Medical Technologies	1.7109 of 5 stars	$23.58 -2.0%	$28.14 +19.4%	-2.0%	$1.37B	$95.13M	N/A	443	Earnings Report Analyst Forecast
CNMD CONMED	1.5064 of 5 stars	$45.79 -1.3%	$41.40 -9.6%	-9.2%	$1.37B	$1.37B	24.66	3,900	Positive News Analyst Upgrade
DRTS Alpha Tau Medical	1.1666 of 5 stars	$14.42 +0.1%	$15.40 +6.8%	+272.6%	$1.30B	N/A	N/A	121

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. OMCL, KMTS, CNMD, DRTS, and AORT

How does ClearPoint Neuro compare to Omnicell?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Summary

How does ClearPoint Neuro compare to CONMED?

Summary

How does ClearPoint Neuro compare to Alpha Tau Medical?

Summary

How does ClearPoint Neuro compare to Artivion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. OMCL, KMTS, CNMD, DRTS, and AORT

How does ClearPoint Neuro compare to Omnicell?

Which has better earnings and valuation, OMCL or CLPT?

Which has more risk and volatility, OMCL or CLPT?

Do insiders and institutionals have more ownership in OMCL or CLPT?

Do analysts recommend OMCL or CLPT?

Does the media prefer OMCL or CLPT?

Is OMCL or CLPT more profitable?

Summary

How does ClearPoint Neuro compare to Kestra Medical Technologies?

Is KMTS or CLPT more profitable?

Do analysts prefer KMTS or CLPT?

Does the media refer more to KMTS or CLPT?

Which has better valuation and earnings, KMTS or CLPT?

Do insiders & institutionals believe in KMTS or CLPT?

Which has more volatility and risk, KMTS or CLPT?

Summary

How does ClearPoint Neuro compare to CONMED?

Do insiders & institutionals believe in CLPT or CNMD?

Which has more risk and volatility, CLPT or CNMD?

Does the media favor CLPT or CNMD?

Do analysts rate CLPT or CNMD?

Which has stronger earnings & valuation, CLPT or CNMD?

Is CLPT or CNMD more profitable?

Summary

How does ClearPoint Neuro compare to Alpha Tau Medical?

Which has more risk and volatility, DRTS or CLPT?

Is DRTS or CLPT more profitable?

Which has preferable valuation and earnings, DRTS or CLPT?

Do analysts rate DRTS or CLPT?

Do insiders & institutionals believe in DRTS or CLPT?

Does the media favor DRTS or CLPT?

Summary

How does ClearPoint Neuro compare to Artivion?

Do insiders and institutionals hold more shares of AORT or CLPT?

Which has more volatility and risk, AORT or CLPT?

Which has stronger valuation & earnings, AORT or CLPT?

Is AORT or CLPT more profitable?

Does the media favor AORT or CLPT?

Do analysts prefer AORT or CLPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools